The BLA (Biologics License Application) for the “HPC-Cord Blood” product, was submitted to FDA on January 7th, 2022, and StemCyte was officially notified on March 8th, 2022, that the submission was acceptable to enter the biologics license quality review process. The “HPC-Cord Blood” is an umbilical cord blood hematopoietic stem cell product intended for unrelated…
eTurboNews artikujt janë vetëm për abonentët. Abonimi është FALAS.
Abonentët identifikohen këtu Klikoni këtu për t'u abonuar FALAS
Abonentët identifikohen këtu Klikoni këtu për t'u abonuar FALAS
ÇFARË TË HIQET KY ARTIKU:
- Product, was submitted to FDA on January 7th, 2022, and StemCyte was officially notified on March 8th, 2022, that the submission was acceptable to enter the biologics license quality review process.
- Is an umbilical cord blood hematopoietic stem cell product intended for unrelated….
- The “HPC-Cord Blood”.
